JP2015157843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015157843A5 JP2015157843A5 JP2015093417A JP2015093417A JP2015157843A5 JP 2015157843 A5 JP2015157843 A5 JP 2015157843A5 JP 2015093417 A JP2015093417 A JP 2015093417A JP 2015093417 A JP2015093417 A JP 2015093417A JP 2015157843 A5 JP2015157843 A5 JP 2015157843A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- pyrido
- dihydro
- phthalazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8668708P | 2008-08-06 | 2008-08-06 | |
| US61/086,687 | 2008-08-06 | ||
| US15103609P | 2009-02-09 | 2009-02-09 | |
| US61/151,036 | 2009-02-09 | ||
| US17308809P | 2009-04-27 | 2009-04-27 | |
| US61/173,088 | 2009-04-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522113A Division JP5984389B2 (ja) | 2008-08-06 | 2009-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017145036A Division JP2018012698A (ja) | 2008-08-06 | 2017-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015157843A JP2015157843A (ja) | 2015-09-03 |
| JP2015157843A5 true JP2015157843A5 (enExample) | 2015-10-15 |
Family
ID=41129519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522113A Active JP5984389B2 (ja) | 2008-08-06 | 2009-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
| JP2015093417A Pending JP2015157843A (ja) | 2008-08-06 | 2015-04-30 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
| JP2017145036A Pending JP2018012698A (ja) | 2008-08-06 | 2017-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522113A Active JP5984389B2 (ja) | 2008-08-06 | 2009-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017145036A Pending JP2018012698A (ja) | 2008-08-06 | 2017-07-27 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8012976B2 (enExample) |
| EP (3) | EP2326650B9 (enExample) |
| JP (3) | JP5984389B2 (enExample) |
| KR (1) | KR101846029B1 (enExample) |
| CN (3) | CN103896942A (enExample) |
| AR (1) | AR072970A1 (enExample) |
| AU (1) | AU2009279944B2 (enExample) |
| BR (1) | BRPI0917119B1 (enExample) |
| CA (1) | CA2732797C (enExample) |
| CY (3) | CY1115022T1 (enExample) |
| DK (2) | DK2767537T3 (enExample) |
| ES (2) | ES2466565T3 (enExample) |
| FR (1) | FR19C1071I2 (enExample) |
| GB (1) | GB2462361A (enExample) |
| HR (1) | HRP20170982T1 (enExample) |
| HU (2) | HUE035295T2 (enExample) |
| IL (1) | IL211070A (enExample) |
| LT (2) | LT2767537T (enExample) |
| LU (1) | LUC00140I2 (enExample) |
| MX (1) | MX2011001328A (enExample) |
| NL (1) | NL301021I2 (enExample) |
| NO (1) | NO2019042I1 (enExample) |
| NZ (1) | NZ591166A (enExample) |
| PL (2) | PL2767537T3 (enExample) |
| PT (2) | PT2326650E (enExample) |
| SG (2) | SG10201809895YA (enExample) |
| SI (2) | SI2767537T1 (enExample) |
| SM (1) | SMT201700312T1 (enExample) |
| TW (2) | TWI448464B (enExample) |
| WO (1) | WO2010017055A2 (enExample) |
| ZA (1) | ZA201100897B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| CA2787844C (en) * | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| MX340319B (es) * | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| WO2011130661A1 (en) * | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| JP5836367B2 (ja) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| CN103282365B (zh) * | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 |
| WO2012166151A1 (en) * | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| RU2018147217A (ru) | 2011-09-30 | 2019-01-18 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr |
| AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
| KR101716012B1 (ko) * | 2011-12-31 | 2017-03-13 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론 |
| KR101684039B1 (ko) * | 2011-12-31 | 2016-12-07 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논 |
| CN115778934A (zh) | 2012-01-20 | 2023-03-14 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| US9855261B2 (en) | 2012-11-08 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
| MX364895B (es) * | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| EP3066084A1 (en) * | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AU2016312011B2 (en) | 2015-08-25 | 2021-02-04 | Beigene, Ltd. | Process for preparing Parp inhibitor, crystalline forms, and uses thereof |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| CN108210461A (zh) * | 2016-12-16 | 2018-06-29 | 中国科学院上海药物研究所 | 一种Talazoparib药物组合物及其应用 |
| CN107573341B (zh) * | 2016-12-29 | 2020-08-14 | 广州丹康医药生物有限公司 | 作为parp抑制剂的新型稠环化合物、其制备方法和应用 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| CN107556312B (zh) * | 2016-12-29 | 2020-04-10 | 广州丹康医药生物有限公司 | 具有parp抑制活性的新型稠环化合物、其制备方法和用途 |
| CN110392687B (zh) | 2017-02-28 | 2022-08-02 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途 |
| WO2018205938A1 (zh) * | 2017-05-08 | 2018-11-15 | 广州丹康医药生物有限公司 | Parp抑制剂、其药物组合物、制备方法和应用 |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| AU2018347331A1 (en) | 2017-10-13 | 2020-04-09 | Merck Patent Gmbh | Combination of a PARP inhibitor and a PD-1 axis binding antagonist |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
| CN108341792B (zh) * | 2018-04-28 | 2021-09-17 | 苏州莱克施德药业有限公司 | 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法 |
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| CN108676888B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种肺部恶性肿瘤易感性预测试剂盒及系统 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| KR20210097124A (ko) | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| US20210355223A1 (en) | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| AU2020274407B2 (en) | 2019-05-14 | 2023-09-28 | Suzhou Four Health Pharmaceuticals Co., Ltd | Quinazoline-2,4-dione derivatives as PARP inhibitors |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
| EP4118105A2 (en) | 2020-03-09 | 2023-01-18 | Pfizer Inc. | Cd80-fc fusion protein and uses thereof |
| JP2023548896A (ja) | 2020-11-13 | 2023-11-21 | ファイザー・インク | タラゾパリブ軟質ゼラチンカプセル剤形 |
| US20240052423A1 (en) | 2020-12-07 | 2024-02-15 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4313034A1 (en) | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| EP4319755A4 (en) | 2021-04-08 | 2025-03-26 | Board of Regents, The University of Texas System | Compounds and methods for theranostic targeting of parp activity |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4089093A1 (en) * | 2021-05-12 | 2022-11-16 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Radiosynthesis of [18f] talazoparib |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4532493A1 (en) | 2022-06-01 | 2025-04-09 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| EP4536216A4 (en) * | 2022-06-08 | 2026-04-08 | Valo Health Inc | TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE |
| CN115572218B (zh) * | 2022-08-29 | 2024-04-16 | 江阴勒森生物科技有限公司 | 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法 |
| EP4585596A4 (en) * | 2022-09-09 | 2025-12-10 | Shanghai Yingli Pharm Co Ltd | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| CN116283924B (zh) * | 2023-01-16 | 2024-07-26 | 四川效佳科技有限公司 | 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US106631A (en) * | 1870-08-23 | Improvement in seed-planter | ||
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| EP0699754B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Method for diagnosing a predisposition for breast and ovarian cancer |
| GB9505538D0 (en) * | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| KR100663147B1 (ko) | 2002-02-19 | 2007-02-28 | 오노 야꾸힝 고교 가부시키가이샤 | 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제 |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| AU2003277674A1 (en) * | 2002-11-12 | 2004-06-03 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| EP1633362B1 (en) * | 2003-05-28 | 2012-09-26 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| WO2005080356A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| WO2010017850A1 (de) | 2008-08-12 | 2010-02-18 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von cycloalkyl-substituierten piperazinverbindungen |
| BRPI0721950A2 (pt) | 2007-08-22 | 2015-09-29 | 4Sc Ag | indolopiridinas como inibidores da proteína de fuso de cinesina |
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| CN101998959B (zh) | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
| HUE035295T2 (en) * | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| MX340319B (es) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| CN103282365B (zh) | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| EP3066084A1 (en) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
-
2009
- 2009-07-27 HU HUE14154664A patent/HUE035295T2/en unknown
- 2009-07-27 CN CN201410003342.9A patent/CN103896942A/zh active Pending
- 2009-07-27 BR BRPI0917119-3A patent/BRPI0917119B1/pt active IP Right Grant
- 2009-07-27 SG SG10201809895YA patent/SG10201809895YA/en unknown
- 2009-07-27 AU AU2009279944A patent/AU2009279944B2/en active Active
- 2009-07-27 CN CN200980139634.2A patent/CN102171214B/zh active Active
- 2009-07-27 DK DK14154664.8T patent/DK2767537T3/da active
- 2009-07-27 SI SI200931668T patent/SI2767537T1/sl unknown
- 2009-07-27 EP EP09805360.6A patent/EP2326650B9/en active Active
- 2009-07-27 PT PT98053606T patent/PT2326650E/pt unknown
- 2009-07-27 NZ NZ591166A patent/NZ591166A/xx unknown
- 2009-07-27 SG SG2013065719A patent/SG193842A1/en unknown
- 2009-07-27 EP EP17161893.7A patent/EP3241832A1/en not_active Withdrawn
- 2009-07-27 WO PCT/US2009/051879 patent/WO2010017055A2/en not_active Ceased
- 2009-07-27 US US12/510,096 patent/US8012976B2/en active Active
- 2009-07-27 MX MX2011001328A patent/MX2011001328A/es active IP Right Grant
- 2009-07-27 LT LTEP14154664.8T patent/LT2767537T/lt unknown
- 2009-07-27 CA CA2732797A patent/CA2732797C/en active Active
- 2009-07-27 KR KR1020117005152A patent/KR101846029B1/ko active Active
- 2009-07-27 CN CN201410640197.5A patent/CN104478875B/zh active Active
- 2009-07-27 EP EP14154664.8A patent/EP2767537B1/en active Active
- 2009-07-27 DK DK09805360.6T patent/DK2326650T3/en active
- 2009-07-27 PL PL14154664T patent/PL2767537T3/pl unknown
- 2009-07-27 SM SM20170312T patent/SMT201700312T1/it unknown
- 2009-07-27 JP JP2011522113A patent/JP5984389B2/ja active Active
- 2009-07-27 SI SI200930881T patent/SI2326650T1/sl unknown
- 2009-07-27 ES ES09805360.6T patent/ES2466565T3/es active Active
- 2009-07-27 ES ES14154664.8T patent/ES2625817T3/es active Active
- 2009-07-27 PT PT141546648T patent/PT2767537T/pt unknown
- 2009-07-27 PL PL09805360T patent/PL2326650T3/pl unknown
- 2009-08-04 GB GB0913474A patent/GB2462361A/en not_active Withdrawn
- 2009-08-05 TW TW098126400A patent/TWI448464B/zh active
- 2009-08-05 AR ARP090102999A patent/AR072970A1/es active IP Right Grant
- 2009-08-05 TW TW103106940A patent/TW201422617A/zh unknown
-
2011
- 2011-02-03 IL IL211070A patent/IL211070A/en active Protection Beyond IP Right Term
- 2011-02-03 ZA ZA2011/00897A patent/ZA201100897B/en unknown
- 2011-03-31 US US13/077,785 patent/US8420650B2/en active Active
-
2013
- 2013-03-06 US US13/787,496 patent/US8999987B2/en active Active
-
2014
- 2014-03-28 CY CY20141100240T patent/CY1115022T1/el unknown
-
2015
- 2015-02-26 US US14/632,825 patent/US9820985B2/en active Active
- 2015-04-30 JP JP2015093417A patent/JP2015157843A/ja active Pending
-
2017
- 2017-05-31 CY CY20171100578T patent/CY1119218T1/el unknown
- 2017-06-29 HR HRP20170982TT patent/HRP20170982T1/hr unknown
- 2017-07-27 JP JP2017145036A patent/JP2018012698A/ja active Pending
- 2017-09-28 US US15/719,534 patent/US10543209B2/en active Active
-
2019
- 2019-11-28 NO NO2019042C patent/NO2019042I1/no unknown
- 2019-11-28 CY CY2019044C patent/CY2019044I2/el unknown
- 2019-12-03 FR FR19C1071C patent/FR19C1071I2/fr active Active
- 2019-12-05 LT LTPA2019522C patent/LTC2767537I2/lt unknown
- 2019-12-11 NL NL301021C patent/NL301021I2/nl unknown
- 2019-12-11 LU LU00140C patent/LUC00140I2/fr unknown
- 2019-12-13 US US16/714,474 patent/US10780088B2/en active Active
- 2019-12-19 HU HUS1900053C patent/HUS1900053I1/hu unknown
-
2020
- 2020-08-21 US US17/000,271 patent/US11364241B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530513A5 (enExample) | ||
| JP7758895B2 (ja) | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 | |
| US20240366608A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| JP6712344B2 (ja) | Ｂｅｔタンパク質阻害剤としての三環式複素環 | |
| ES3021205T3 (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| US9844553B2 (en) | Pyrazolopyridyl compounds as aldosterone synthase inhibitors | |
| JP4513919B2 (ja) | ジヒドロピラゾロピリミジノン誘導体 | |
| JP2013518892A5 (enExample) | ||
| AU2016365366B2 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| CN104478875B (zh) | 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
| JP2024105340A (ja) | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 | |
| JP2025536259A (ja) | 三環式化合物及びその使用 | |
| TW202039489A (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
| US20240124422A1 (en) | Mutant pi3k-alpha inhibitors and their use as pharmaceuticals | |
| AU2017311645A1 (en) | Pyridopyrimdinone CDK2/4/6 inhibitors | |
| JP2022541127A (ja) | キナーゼ阻害剤としての置換された縮合複素芳香族二環式化合物およびその使用 | |
| US9260435B2 (en) | Substituted imidazopyrazines as Akt kinase inhibitors | |
| JP2019504821A (ja) | ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン | |
| CN114790209A (zh) | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 | |
| JPWO2009054332A1 (ja) | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 | |
| JP7247092B2 (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| JP2024540483A (ja) | Ｃｄｋ２阻害剤及びその製造方法及び使用方法 | |
| CN112457306A (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
| EP3749669A1 (en) | Ahr modulators |